Tevogen Explores Acquisition of Sciometrix’s Clinicus Digital Platform
Key Takeaways
Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a New Jersey-based healthcare company, has announced it has signed a non-exclusive, non-binding Letter of Intent (LoI) with Sciometrix Inc., a healthcare technology provider based in Michigan. The potential deal would grant Tevogen a majority voting interest in Sciometrix and its Clinicus digital care management platform, signaling a significant shift toward integrating advanced technology into Tevogen’s healthcare offerings.
Aiming to Transform Healthcare
The proposed acquisition is part of Tevogen’s strategy to enhance its digital care and patient engagement capabilities while transitioning into a revenue-generating enterprise. By integrating Sciometrix’s Clinicus platform and remote patient monitoring tools with Tevogen’s AI-driven initiatives, the company hopes to further its mission of delivering innovative and efficient healthcare solutions.
According to Tevogen, the potential acquisition could accelerate its commercialization readiness by facilitating better tracking of patient outcomes and aligning with value-based care models. Sciometrix’s Clinicus platform, which includes predictive analytics and care optimization features, is expected to enhance Tevogen’s data capabilities and strengthen its AI-powered initiatives such as Tevogen.AI. The company believes this integration could also optimize clinical trials and create a unique "biotech-plus-services" model aimed at improving patient access and streamlining the healthcare process.
sbb-itb-8f61039
Leaders Weigh In
Abhishek Sharma, Founder and Chief Executive Officer of Sciometrix, highlighted the potential impact on patients and the company’s growing presence in digital healthcare. "Today marks a major milestone for Sciometrix and Clinicus and the many patients who rely on our high-quality, cost-effective digital healthcare platform to deliver healthcare in their own environment. Our comprehensive care management service has achieved major milestones in the past year, resulting in Sciometrix becoming a top 25 digital healthcare company in the USA. With the addition of Tevogen.AI’s capabilities, we aim to jump into the top 10 next year."
Dr. Ryan Saadi, Founder and Chief Executive Officer of Tevogen, emphasized the company’s broader vision for the acquisition. "Tevogen strategic acquisitions are not just about adding revenue and earnings, they are about the infrastructure and dedication needed to change lives. Tevogen began in T cell therapy, evolving into a diversified healthcare company, with 2026 revenue goal, advanced cell therapy pipeline, and a leading AI initiative in drug development and clinical trials."
Next Steps and Considerations
While the LoI is an important first step, the potential acquisition remains subject to several factors, including due diligence, negotiation and execution of definitive agreements, and regulatory approvals. Tevogen has also indicated it is exploring additional transactions in related life sciences fields, though the company cautioned that no outcomes can be guaranteed.
If finalized, the acquisition could further support Tevogen’s goal of aligning advanced immunotherapies with digital tools for longitudinal patient monitoring and payer reporting, an essential step in advancing value-based care models. The partnership also reflects Tevogen’s commitment to sustainable innovation and broadening patient access.
About the Companies
Tevogen is a socially integrated healthcare enterprise focused on affordability, efficiency, and scientific rigor. Its initiatives include precision T cell therapies, AI-driven drug development platforms, and scalable healthcare solutions. The company’s ExacTcell™ platform underpins its programs in virology, oncology, and neurology.
Sciometrix, on the other hand, specializes in enterprise care management, digital patient engagement, and predictive analytics. Its Clinicus platform is recognized as a leading tool for value-based care solutions across the United States.
Looking Ahead
As Tevogen evaluates the potential acquisition of Sciometrix, the healthcare industry will be watching closely to see how this partnership could reshape the intersection of biotechnology and digital care. For now, both companies remain optimistic about the opportunities ahead and their shared vision for advancing patient-centered healthcare.
Author
